March 16th 2023
Findings from the phase 2 Study CDRB436G2201 trial have led the FDA to approve dabrafenib combined with trametinib for pediatric patients with BRAF V600E-mutated low-grade glioma who require systemic therapy.
February 27th 2023
Engaging Oncology Peers in Discussions Around Precision MedicineFebruary 3rd 2023
In an interview with Targeted Oncology™, Manmeet Ahluwalia, MD, discussed the importance of the Inaugural Miami Cancer Institute Precision Medicine Oncology Symposium, what to expect from his presentation on brain metastases, and what to expect from presentations by other experts.
Taking on the Challenge to Develop New Therapies for Pediatric Solid TumorsJanuary 31st 2023
Both pediatric brain cancers and sarcomas have an extremely dismal outcome in the relapse setting, according to Catherine Bollard, MD. A new Cancer Grand Challenge aims to address the issue with the development of new therapies.
FDA Grants Orphan Drug Designation to Azeliragon for Patients with GlioblastomaJanuary 10th 2023
Azeliragon has been granted an orphan drug designation by the FDA for patients with glioblastoma after previous trials demonstrated the agent to be well-tolerated in Alzheimer’s disease.
Ongoing Research in Brain Tumor Therapies Provides Hope for the FutureDecember 2nd 2022
Primary brain cancers are aggressive, resulting in low survival rates, and pose significant challenges to effective treatment, but ongoing studies signal hope for patients with there tumors.
World Neuroendocrine Cancer Awareness Day: Therapeutic Options for Well-differentiated NETsNovember 10th 2022
Ajaz M. Khan, MD, MBA, CPE, a medical oncologist and chair of the CTCA Department of Medical Oncology, explores available treatments for patients with well-differentiated neuroendocrine tumors.
ODAC Votes Against Omburtamab for Neuroblastoma with CNS/ Leptomeningeal MetastasesOctober 28th 2022
In a unanimous vote, the FDA’s Oncologic Drugs Advisory Committee has voted that there is not enough evidence to conclude omburtamab improves overall survival in neuroblastoma with central nervous system/leptomeningeal metastases.
Gender-Specific AI Model Advances Understanding of Glioblastoma Progression and Treatment ResponseSeptember 21st 2022
Distinguishing on current imaging between disease progression and pseudo progression in patients with glioblastoma is one of the most difficult clinical problems, according to Manmeet Ahluwalia, MD and Pallavi Tiwari, PhD.
Promising Safety and Efficacy Seen With Higher-Dose Rhenium-186 Nanoliposome in Recurrent GliomaSeptember 9th 2022
Rhenium-186 nanoliposome at doses exceeding 100 Gy showed promising results in patients with recurrent glioma, according to phase 1 findings from the ReSPECT-GBM trial presented at ESMO 2022.
Paxalisib Plus Radiotherapy Reveals Promising ORR in Patients With Brain MetastasesAugust 8th 2022
The combination of paxalisib and radiotherapy exhibited complete or partial responses in all patients with brain metastases, according to interim data from an ongoing phase I clinical trial.
FDA Grants Orphan Drug and Fast Track Designations to Sonodynamic Therapy in Brain CancersJuly 13th 2022
An orphan drug designation and a fast track designation have been granted by the FDA to a novel sonodynamic therapy platform as a potential treatment for patients with recurrent glioblastoma and other malignant gliomas.
Doublet Therapy Shows Better Response Vs Chemotherapy in BRAF V600+ Pediatric Low-Grade GliomaJune 8th 2022
According to Eric Bouffet, MD, results from a phase 2 study presented during the 2022 ASCO Annual Meeting show how important it is to document as early as possible the molecular alterations that are present in this type of tumor.